Biocryst Pharmaceuticals, Inc.

Island Pharmaceuticals Ltd.

Other

Biocryst Pharmacueticals, Inc.

Yarlagadda Sudhakara Babu

Pravin L Kotian

V Satish Kumar

Weihe Zhang

Minwan Wu

Venkat R Chintareddy

Pooran Chand

Shanta Bantia

Yahya El-Kattan

Krishnan Raman

Lakshminarayana Vogeti

Peng-Cheng Lu

Wei Lv

Shane Arnold

John Michael Kilpatrick

Trung Xuan Nguyen

Zhao Dang

John A Montgomery

Ajit K Ghosh

R Scott Rowland

William P Sheridan

Ming Luo

Wayne J Brouillette

Satish V Kumar

Tsu-Hsing Lin

Shri Niwas

Philip E Morris, Jr

Venkatram Reddy Atigadda

David A Walsh

Vivekanand P Kamath

J Claude Bennett

Walter Gowan

Scott R Rowland

Amanda Mathis

Philip Breitfeld

Satish Kumar V

The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents.

Methods and compositions for inhibition of polymerase

Disclosed are methods of preparing Compound I, and salts thereof. The methods of preparing Compound I are suitable for use on process scale.

Process-scale synthesis of a plasma kallikrein inhibitor

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula I, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity.

Pyrrolo 12.3-dipyrimidine compounds and analogues thereof

Provided are compounds of the formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, for use in treating or suppressing a SARS-CoV-2 infection in a subject. A novel dosing regimen for administration of the disclosed compounds is also provided comprising administering at least one loading dose and at least one maintenance dose of the disclosed compound. The compounds of the disclosure are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with the dosing regimen described.

Methods, compositions, and dosing regimens for treatment of SARS-CoV-2 infections

Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.

Crystalline salts of a plasma kallikrein inhibitor

Human plasma kallikrein inhibitors

The invention provides unit dosage forms, kits, and methods useful for treating viral infections.

Antiviral treatments

Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.

Imidazole-containing inhibitors of ALK2 kinase

Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of viral RNA polymerase. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or suppression of a Zika virus infection or a disease or condition associated with a Zika virus infection.

Methods and compositions for treatment of Zika virus infection

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Growing community of inventors

Birmingham, AL, United States of America

Yarlagadda Sudhakara Babu